50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Clinical Results

Saturday, December 6, 2008: 5:30 PM-7:30 PM

Hall A (Moscone Center)

Autologous Bone Marrow-Derived Stem Cell Therapy: A Promising and Prospective Approach in the Treatment of Patients with Severe Buerger's Disease

Zoltan Boda¹^*, Miklos Udvardy¹^*, Katalin Razso¹^*, Mariann Szarvas¹^*, Zsolt Olah¹^*, Peter Ilonczai¹^*, Judit Toth²^*, Laszlo Jambor²^*, Janos Hunyadi³^*, Tamas Sipos³^*, Gabriella Kovacs³^*, Janos Kappelmayer⁴^*, Katalin Farkas⁵^*, Zoltan Vereb⁶^* and Eva Rajnavolgyi⁶^*

¹2nd Department of Internal Medicine, University of Debrecen, Debrecen, Hungary
²Department of Radiology, University of Debrecen, Debrecen, Hungary
³Cell Therapy Center, University of Debrecen, Debrecen, Hungary
⁴Department of Clinical Biochemistry and Molecular Pathology, University of Debrecen, Debrecen, Hungary
⁵Internal Medicine, St. Imre County Hospital, Budapest, Hungary
⁶Department of Immunology, University of Debrecen, Debrecen, Hungary

1136

12 Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL

John F. DiPersio, MD, PhD¹, Ivana NM Micallef²^*, Patrick J. Stiff, MD³, Brian J. Bolwell, MD⁴, Richard Thomas Maziarz, MD⁵, Gary Bridger, PhD⁶^* and Gary Calandra, MD, PhD⁷

¹School of Medicine, Washington University, Saint Louis, MO
²Mayo Clinic, Rochester, MN
³Loyola Univ. Med. Ctr., Maywood, IL
⁴Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁵OR Health Sciences Univ., Portland, OR
⁶Genzyme, Cambridge, MA
⁷Genzyme, Cresco, PA

1137

High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL

Stephen D. Smith, MD, Brian Bolwell, MD^*, Anjali Advani, MD^*, Steven Andresen, DO^*, Josephine Chan^*, Robert Dean, MD^*, Eric Hsi, MD^*, Matt Kalaycio, MD^*, Brad Pohlman, MD^*, Lisa Rybicki, MS^*, Ronald Sobecks, MD^* and John Sweetenham, MD^*

Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1138

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT)

Umeer Ashraf, MD¹^*, Ritika Mahajan, MBBS²^*, Theresa Hahn, PhD², Shannon L Smiley, MD²^*, Philip L. McCarthy, MD², Zale P. Bernstein, MD², Asher Alban Chanan-Khan, MD², Minoo Battiwala³^*, Myron S. Czuczman, MD² and Francisco J. Hernandez-Ilizaliturri, MD²

¹Department of Medicine, SUNY Buffalo,Sisters of Charity Hospital, Buffalo, NY
²Roswell Park Cancer Institute, Buffalo, NY
³Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY

1139

Activated B-Cell (ABC) Profile Does Not Have An Inferior Outcome Compared to Germinal Center B-Cell (GCB) Profile Determined by Immunohistochemistry Tissue Microarray in Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and Dose-Dense and High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT)

Annalisa Chiappella¹^*, Domenico Novero²^*, Alessandra Tucci¹^*, Maria Giuseppina Cabras¹^*, Anna Marina Liberati¹^*, Giovannino Ciccone³^*, Flavia Salvi¹^*, Emanuele Angelucci¹^*, Chiara Bottelli¹^*, Barbara Botto¹^*, Fabio Facchetti²^*, Lorenzo Falchi¹^*, Chiara Frairia¹^*, Alessandro Levis¹^*, Lorella Orsucci¹^*, Tommasina Perrone¹^*, Enrico Maria Pogliani¹^*, Delia Rota-Scalabrini¹^*, Anna Tonso¹^*, Giorgio Inghirami²^* and Umberto Vitolo¹

¹On the behalf of GIMURELL, Hematology 2, AOU San Giovanni Battista, Turin, Italy
²Pathology Department, University, Turin, Italy
³Unit of Epidemiology; CPO Piemonte, University, Turin, Italy

1140

Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO)

Issa F Khouri, M.D.¹, Roland Bassett²^*, Barry Samuels³^*, Farzaneh Maadani¹^*, Grace-Julia Okoroji¹^*, Robyn Harrell²^*, Martin Korbling¹^*, Leandro de Padua Silva¹^*, Amin Alousi¹^*, Chitra Hosing¹^*, Sergio Giralt¹^*, Marcos de Lima¹^*, Paolo Anderlini¹^*, Uday Popat¹^*, Rosamar Valverde¹^*, Yvonne Hsu¹^*, Fredrick Hagemeister⁴^*, Peter McLaughlin⁴^* and L. Jeffrey Medeiros⁵^*

¹Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX
²Division of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX
³Diagnostic Radiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
⁴Lymphoma, The University of Texas M. D. Anderson Cancer Center, Houston, TX
⁵Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

1141

Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission

Issa F Khouri¹, Adriana Lopez²^*, Grace-Julia Okoroji³^*, Martin Korbling, MD³^*, Gloria McCormick⁴^*, Yvonne Hsu³^*, Leandro de Padua⁵^*, Amin M. Alousi⁵^*, Chitra M. Hosing⁵^*, Partow Kebriaei, MD⁶, Gabriela Rondon⁷^*, Sergio A Giralt, MD⁵^*, Marcos J. de Lima⁵^*, Paolo Anderlini³^*, Uday R Popat⁸^*, Muzaffar H. Qazilbash⁵^*, Richard E. Champlin⁹^* and Barbara Pro¹⁰^*

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Quantitative Sciences Division, UT M.D. Anderson Cancer Center, Houston, TX
³Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX
⁴Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX
⁵Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX
⁶Dept. of Stem Cell Transplantation, UTMD Anderson Cancer Center, Houston, TX
⁷Department of Stem Cell Transplantation & Cell Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸Stem Cell Transplantation and Cellular Therapy, U.T. M.D. Anderson Cancer Center, Houston, TX
⁹Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
¹⁰Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston, TX

1142

Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease

Constantine S Tam¹, Roland Bassett²^*, Celina Ledesma³^*, Martin J. Korbling³^*, Grace-Julia Okoroji³^*, Robyn Harrell²^*, Yvonne Hsu³^*, Leandro De Padua Silva³^*, Amin M. Alousi³^*, Chitra M Hosing⁴^*, Partow Kebriael³^*, Gabriela Rondon⁴^*, Sergio Giralt³^*, Marcos De Lima³, Paolo Anderlini³^*, Uday Popat³^*, Muzaffar H. Qazilbash³, Barry Samuels²^*, Richard E Champlin³^* and Issa F Khouri³^*

¹Leukemia, UT MD Anderson Cancer Center, Houston, TX
²UT MD Anderson Cancer Center, Houston, TX
³Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
⁴Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX

1143

The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

Lihua Pan, MD, PhD¹, Katherine A Guthrie, Ph.D.²^*, Brian G. Till, MD³, Oliver W. Press, MD, PhD², John M. Pagel, MD, PhD⁴, Stephen Petersdorf, MD⁵, William Bensinger, MD⁶^*, Leona Holmberg, MD, PhD², David G. Maloney, MD, PhD⁷ and Ajay Gopal, MD⁵

¹Medical Oncology, Fed Hutchinson Cancer Research Center, Seattle, WA
²Fred Hutchinson Cancer Research Center, Seattle, WA
³Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Fred Hutchinson Cancer Research Ctr., Seattle, WA
⁵Seattle Cancer Care Alliance, Seattle, WA
⁶Fred Hutchinson Cancer, Seattle, WA
⁷Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA

1144

Radioimmunotherapy (⁹⁰Y-Zevalin®) Combined with BEAM Conditioning Regimen and Autologous Stem Cell Transplantation for the Treatment of Non Hodgkin Lymphomas: Results of An Italian Multicenter Study

Vincenzo Pavone¹^*, Anna Mele²^*, Antonio Rana¹^*, Cosimo Del Casale¹^*, Anna Rita Messa¹^*, Giuseppina Greco¹^*, Silvia Sibilla¹^*, Rosa De Francesco¹^*, Vincenzo Frusciante³^*, Antonio Varraso³^*, Umberto Vitolo, MD⁴, Barbara Botto⁵^*, Giusppe Milone, MD⁶^*, Salvatore Leotta⁶^*, Pasquale Iacopino⁷^*, Giuseppe Console⁶^*, Attilio Olivieri, MD⁸, Michele Cimminiello⁸^*, Vincenzo Mettivier⁹^*, Luca Pezzullo⁹^*, Donatella Baronciani¹⁰^*, Emanuele Angelucci¹¹, Maurizio Musso¹²^*, Renato Scalone¹³^*, Nicola Cascavilla¹⁴^*, Potito Rosario Scalzulli¹⁵^*, Silvana Capalbo¹⁶^*, Giacomo Loseto¹⁷^*, Giovanni Quarta¹⁸^*, Pellegrino Musto, MD¹⁹^*, Margherita Caputo¹^* and Angelo Ostuni¹^*

¹Haematology and Transfusion Medicine, AZIENDA OSPEDALIERA CARDINALE PANICO, Tricase, Italy
²Haematology and Transfusion Medicine, A, Tricase, Italy
³Nuclear Medicine, Hospital Casa Sollievo della Sofferenza,, San Giovanni Rotondo, Italy
⁴Ematologia 2, Italian Multiple Myeloma Network, GIMEMA, Turin, Italy
⁵Haematology, HOSPITAL SAN GIOVANNI BATTISTA, Torino, Italy
⁶Ospedale Ferrarotto, Bone Marrow Unit, Catania, Italy
⁷Hematology, Bone Marrow Unit, Reggio Calabria, Italy
⁸Ospedale San Carlo, Potenza, Fano, Italy
⁹Hematology, A.Cardarelli Hospital, Naples, Italy
¹⁰Haematology, HOSPITAL BUSINCO, Cagliari, Italy
¹¹Ematologia-Cagliari, Italy
¹²Ematologia, Ospedale La Maddalena Palermo, Palermo, Italy
¹³Oncoematologia e TMO, Dipartimento Oncologico La Maddalena, Palermo, Palermo, Italy
¹⁴Hematology, Hospital "CASA SOLLIEVO DELLA SOFERENZA" I.R.C.C.S., San Giovanni Rotondo, Italy
¹⁵Hematology, Hospital "CASA SOLLIEVO DELLA SOFFERENZA" I.R.C.C.S., San Giovanni Rotondo, Italy
¹⁶Hematology, Ospedali Riuniti, Foggia, Italy
¹⁷Haematology, hOSPITAL PERRINO, Brindisi, Italy
¹⁸Ematologia, Ospedale di Brindisi, Brindisi, Italy
¹⁹Ematologia e Trapianto Cellule Staminali, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (PZ), Italy

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

733.P1.55 Clinical Results - Autologous Transplantation Poster I